

a
cont.
allow or promote the expression of a gene of interest positioned downstream of said nucleotide sequence.

a
2
14. (Amended) Retroviral vector according to claim 12 [or 13], in which the encapsidation region is derived from a murine retrovirus, especially from an MoMLV, or from a VL30-type retrotransposon and the IRES site comprises a nucleotide sequence [as defined in claim 6] which is substantially homologous or identical to the sequence presented in the sequence identifier SEQ ID NO: 2:

- (i) starting at nucleotide 1 and ending at nucleotide 578,
- (ii) starting at nucleotide 265 and ending at nucleotide 578, or
- (iii) starting at nucleotide 452 and ending at nucleotide 578.

a
2
19. (Amended) Cell comprising a vector according to [one of claims 8 to 17] claim 8 or infected with a viral particle [according to claim 18] generated from a viral vector according to claim 8.

20. (Amended) Use of a vector according to [one of claims 8 to 17] claim 8, of a viral particle generated from a viral vector according to claim [18] 8 or of a cell comprising a vector according to claim 8 or infected with a virus particle generated from viral vector according to claim [19] 8, for the preparation of a pharmaceutical composition intended for the treatment and/or for the prevention of a disease which is treatable by gene therapy.

a³ cont.

21. (Amended) Use of a vector according to [one of claims 8 to 17] claim 8, of a viral particle generated from a viral vector according to claim [18] 8 or of a cell comprising a vector according to claim 8 or infected with a viral vector according to claim [19] 8 for the preparation of one or more polypeptides of interest by the recombinant route or for the protection of a transgenic animal.

Sub C2

22. (Amended) Pharmaceutical composition comprising, as therapeutic or prophylactic agent, a vector according to [one of claims 8 to 17] claim 8, a viral particle generated from a viral vector according to claim [18] 8, a cell comprising a vector according to claim [19] 8 or infected with a viral particle generated from a viral vector according to claim 8, or a polypeptide [of interest obtained according to the use according to claim 21] prepared from said vector, viral particle or cell, in combination with a pharmaceutically acceptable vehicle.

a⁴

24. (Amended) Use of a vector according to [one of claims 8 to 17] claim 8, of a viral particle [according to claim 18] generated from a viral vector according to claim 8 or of a pharmaceutical composition [according to claim 22 or 23] prepared from said vector or viral particle, for the transfection or infection of pluripotent cells, especially pluripotent cells of the central nervous system.

Please amend the remaining claims as follows:

Claim 5, page 38, line 22, please change "one of claims 1 to 4" to --claim 1--.